Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 19/20 | 0.79 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.79 |
| ▸ | MAPK8 | P45983 | 16/20 | 0.79 |
| ▸ | MAPK9 | P45984 | 16/20 | 0.79 |
| ▸ | MAPK10 | P53779 | 16/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4354680 | 0.92 | MAPK1 (0.78) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14506616 | 0.88 | MAPK1 (1.00) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL5622776 | 0.80 | MAPK1 (0.74) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4349216 | 0.80 | MAPK1 (0.74) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14506621 | 0.79 | MAPK1 (0.74) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14506584 | 0.79 | MAPK1 (0.72) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14506689 | 0.79 | MAPK1 (0.73) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14506599 | 0.78 | MAPK1 (0.68) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14506605 | 0.77 | PIK3CA (0.68) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14506653 | 0.76 | MAPK1 (0.75) | MAPK1PIK3CAMAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277219-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2012-11-01 | — | — | US | disclosed |
| US-20120277219-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2012-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277219-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | PNPO, PDXK, MKI67 | MAPK1 460/4885PIK3CA 537/4885MAPK8 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.